Post-metastasis survival | Overall survivall | |||||||
---|---|---|---|---|---|---|---|---|
Variables | Univariate Analysis | P a | Multivariate Analysis | P a | Univariate Analysis | P a | Multivariate Analysis | P a |
Age | 1.485 (1.097-2.010) | 0.010 | 1.537 (1.038-2.277) | 0.032 | 1.734 (1.277-2.355) | < 0.001 | 1.424 (1.027-1.974) | 0.034 |
Sex | 1.018 (0.712-1.458) | 0.921 | - | - | 1.022 (0.714-1.463) | 0.905 | - | - |
T classification | 1.298 (0.948-1.778) | 0.104 | - | - | 1.774 (1.281-2.456) | 0.001 | 1.326 (0.936-1.876) | 0.112 |
N classification | 1.224 (0.809-1.852) | 0.339 | - | - | 1.758 (1.150-2.688) | 0.009 | 1.395 (0.905-2.150) | 0.131 |
M classification | 0.938 (0.625-1.408) | 0.758 | - | - | 3.010 (1.965-4.612) | < 0.001 | 1.290 (0.766-2.172) | 0.338 |
EBV VCA-lgA | 1.490 (1.033-2.148) | 0.033 | 1.342 (0.920-1.958) | 0.127 | 1.348 (0.935-1.942) | 0.110 | - | - |
EBV EA-lgA | 1.171 (0.803-1.710) | 0.412 | - | - | 1.199 (0.820-1.753) | 0.349 | - | - |
DFI | 0.818 (0.676-0.991) | 0.040 | 1.019 (0.796-1.304) | 0.881 | 0.326 (0.263-0.404) | < 0.001 | 0.379 (0.294-0.490) | < 0.001 |
Metastasis site | 1.846 (1.357-2.512) | < 0.001 | 1.295 (0.779-2.153) | 0.319 | 1.964 (1.439-2.682) | < 0.001 | 1.561 (0.967-2.520) | 0.068 |
Metastasis number | 1.813 (1.295-2.539) | 0.001 | 1.274 (0.705-2.301) | 0.422 | 1.970 (1.403-2.768) | < 0.001 | 1.284 (0.761-2.097) | 0.365 |
Metastasis size | 0.952 (0.699-1.296) | 0.754 | - | - | 0.689 (0.505-0.941) | 0.019 | 0.922 (0.664-1.281) | 0.629 |
Recurrence | 1.785 (1.125-2.832) | 0.014 | 1.429 (0.778-2.625) | 0.250 | 1.197 (0.755-1.896) | 0.444 | - | - |
Treatment modalityb | 0.440 (0.302-0.641) | < 0.001 | 0.583 (0.355-0.960) | 0.034 | 0.454 (0.321-0.660) | < 0.001 | 0.566 (0.374-0.857) | 0.007 |
Chemotherapy cyclec | 0.828 (0.612-1.122) | 0.828 | - | - | 1.143 (0.842-1.552) | 0.392 | - | - |
-Chemotherapy effectd | 2.305 (1.016-5.228) | 0.046 | 1.243 (0.511-3.026) | 0.632 | 1.603 (0.708-3.627) | 0.258 | - | - |